- Home
- CRDL vs IHD Comparison
CRDL vs IHD Comparison
Compare CRDL & IHD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CRDL
- IHD
- Stock Information
- Founded
- CRDL 2017
- IHD 2011
- Country
- CRDL Canada
- IHD United States
- Employees
- CRDL N/A
- IHD N/A
- Industry
- CRDL Biotechnology: Biological Products (No Diagnostic Substances)
- IHD Investment Managers
- Sector
- CRDL Health Care
- IHD Finance
- Exchange
- CRDL Nasdaq
- IHD Nasdaq
- Market Cap
- CRDL 90.4M
- IHD 108.0M
- IPO Year
- CRDL N/A
- IHD N/A
- Fundamental
- Price
- CRDL $1.07
- IHD $6.41
- Analyst Decision
- CRDL Strong Buy
- IHD
- Analyst Count
- CRDL 2
- IHD 0
- Target Price
- CRDL $9.00
- IHD N/A
- AVG Volume (30 Days)
- CRDL 781.9K
- IHD 27.7K
- Earning Date
- CRDL 11-13-2025
- IHD 01-01-0001
- Dividend Yield
- CRDL N/A
- IHD 10.32%
- EPS Growth
- CRDL N/A
- IHD N/A
- EPS
- CRDL N/A
- IHD N/A
- Revenue
- CRDL N/A
- IHD N/A
- Revenue This Year
- CRDL N/A
- IHD N/A
- Revenue Next Year
- CRDL N/A
- IHD N/A
- P/E Ratio
- CRDL N/A
- IHD N/A
- Revenue Growth
- CRDL N/A
- IHD N/A
- 52 Week Low
- CRDL $0.77
- IHD $4.49
- 52 Week High
- CRDL $2.24
- IHD $5.47
- Technical
- Relative Strength Index (RSI)
- CRDL 44.27
- IHD 75.71
- Support Level
- CRDL $1.04
- IHD $6.19
- Resistance Level
- CRDL $1.16
- IHD $6.27
- Average True Range (ATR)
- CRDL 0.06
- IHD 0.06
- MACD
- CRDL 0.00
- IHD 0.01
- Stochastic Oscillator
- CRDL 18.00
- IHD 88.35
About CRDL Cardiol Therapeutics Inc.
Cardiol Therapeutics Inc is a clinical-stage life sciences company focused on the research and clinical development of anti-inflammatory and anti-fibrotic therapies for the treatment of heart diseases. The company's main product candidate, CardiolRx, is a pharmaceutically manufactured oral cannabidiol formulation that is being clinically developed for use in heart diseases. Cardiol has received Investigational New Drug Application authorization from the United States Food and Drug Administration to conduct clinical studies to evaluate the efficacy and safety of CardiolRx in two diseases affecting the heart which are a Phase II multi-national trial, the ARCHER trial, in acute myocarditis; and a Phase II multi-center open-label pilot study in recurrent pericarditis.
About IHD Voya Emerging Markets High Income Dividend Equity Fund
Voya Emerging Markets High Dividend Equity Fund is a diversified closed-end management investment company. Its primary investment objective is to provide total return through a combination of current income, capital gains, and capital appreciation. The company seeks to achieve its investment objectives by investing principally in a portfolio of equity securities, and issuers in emerging market countries. The Fund will also normally seek to secure gains and enhance the stability of returns over a market cycle by writing (selling) call options on selected exchange-traded funds (ETFs) and/or international, regional, or country indices of equity securities, and/or on equity securities.